Attana receives follow up contract research order from global pharma company
Attana has received a follow up contract research order from an global pharma company with headquarter in Europe. The contract is the results of the previous experiments and has an expanded range. The experiments are based on Attana’s patented cell-based biosensor and will included detailed interaction analysis between biopharmaceutical molecules and specific cells.
Attana’s application specialists will perform experiments where the interactions between a specific target receptor in the cell membrane of three cell types and a number of different biopharmaceutical molecules with therapeutic potential. The molecules will be characterized with respect to interaction kinetics and binding affinity.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release does not affect the share price, but is of general interest for the share holders and hence should be communicated.
This is information that Attana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at March 13 CET on 07.00 2018
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact email@example.com.